BioCentury | Nov 10, 1997
Clinical News

Biomira regulatory update

The FDA granted 510(k) clearance for Truquant BR RIA, BIOMF's breast cancer diagnostic, as an aid in monitoring response to therapy in patients with Stage IV breast cancer. In 1996, the FDA approved the blood...
BioCentury | Aug 18, 1997
Clinical News

Chiron regulatory update

...FDA 510(k) marketing clearance for its ACS:180 BR blood test for the breast cancer antigen CA 27.29...
BioCentury | Jun 30, 1997
Clinical News

Truquant BR Radioimmunoassay for the CA 27 data

...such as bone scans. Biomira Inc. (BIOMF), Edmonton, Alberta Product: Truquant BR Radioimmunoassay for the CA 27.29...
BioCentury | May 27, 1997
Company News

Biomira, Tosoh Corp. deal

Tosoh exercised its option to license BIOMF's B27.29 antibody against the CA27.29 antigen for breast cancer diagnosis. Tosoh will incorporate the antibody in its breast cancer immunoassays. BIOMF will receive an upfront payment and a...
BioCentury | Apr 8, 1996
Clinical News

Biomira regulatory update

The FDA approved Truquant BR RIA, BIOMF's Biomira Diagnostics Inc. subsidiary's breast cancer diagnostic to detect recurrent disease. The blood test detects the presence of CA27.29 antigen, a breast tumor marker. BIOMF expects the test...
BioCentury | Dec 18, 1995
Company News

Biomira Inc, Immunex deal

BIOMF and IMNX agreed to co-promote BIOMF's Truquant BR, a diagnostic for the detection of recurrent Stage II and III breast cancer. The product, manufactured by BIOMF's Biomira Diagnostics subsidiary, received an approvable letter from...
Items per page:
1 - 6 of 6